Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lisaftoclax,Acalabrutinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Ascentage Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Companies will study the combination of Ascentage's APG-2575 and Acerta's CALQUENCE® (acalabrutinib), evaluating the efficacy and safety of this combination therapy in patients with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL)/small lymp...
Product Name : APG-2575
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 21, 2020
Lead Product(s) : Lisaftoclax,Acalabrutinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Ascentage Pharma
Deal Size : Undisclosed
Deal Type : Collaboration